Clinical trial
A Phase 3, Multicenter, Randomized, Open-Label Trial Investigating the Safety, Tolerability and Efficacy of Palopegteriparatide Administered Subcutaneously Daily at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
NCT07081997 is registered in ClinicalTrials.gov with Ascendis Pharma Bone Diseases A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Randomized, Open-Label Trial Investigating the Safety, Tolerability and Efficacy of Palopegteriparatide Administered Subcutaneously Daily at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
- Lead sponsor
- Ascendis Pharma Bone Diseases A/S
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- May 7, 2026
- Completion date
- June 30, 2028
- Enrollment
- 36 (estimated)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.